While almost all U.S. neurologists believe that the recently reported deaths in Gilenya-treated multiple sclerosis (MS) patients are at least somewhat related to the patients’ treatment with Novartis’ Gilenya, overall satisfaction with Gilenya and perceptions of Gilenya’s safety and tolerability have not changed significantly since the publication of the reports. And, despite potential concerns, neurologists continue to project increased use of Gilenya in the next six months. However, 47 percent of neurologists do report discomfort with Gilenya’s risk-benefit profile compared to 26 percent of neurologists who were surveyed last quarter, suggesting that the impact of the U.S. and EU safety review may yet to be fully realized. One respondent made the following statement, reflective of the “wait and see” attitude expressed by many surveyed neurologists: “If the deaths are clearly shown to be related to Gilenya, I think it will be disastrous for the product. For the moment, I will withhold judgment, but I will advise prospective patients of this issue.
Comments are appreciated. Note that All comments are moderated
If not yet receiving our weekly e-Newsletter – Click here to: REGISTER –
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
…………………………
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
